FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density

[9-10-2015] The U.S. Food and Drug Administration (FDA) has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures and added new information about decreased bone mineral density.

Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news